Assessing the budget impact of a new treatment for the management of a chronic disease
Development of a budget impact model (BIM) to demonstrate the economic value and cost savings of an anti-obesity medication (AOM)
Our client required a global health technology assessment (HTA) compliant BIM to demonstrate the value of introducing their product to the obesity treatment landscape. The model needed to be flexible to facilitate country adaptations in order to support HTA submissions globally. Obesity is associated with multiple comorbidities such as diabetes, heart disease and hypertension, which contribute largely to the burden placed on healthcare budgets. It was imperative the model considered such comorbidities to estimate the true value associated with reductions in obesity levels. Finally, it was of particular importance to our client that the model be user friendly and aesthetically pleasing.
A flexible, HTA compliant, global BIM was developed demonstrating the cost saving potential of an antiobesity medication (AOM) for the treatment of obesity. The global BIM’s flexibility allowed end-users to update the BIM in line with their relevant settings, as the label varied among countries. For example, they could include or exclude different populations, such as patients with diabetes. The model accounted for drug costs, treatment related costs and cost savings stemming from a decrease in the levels of obesity and its comorbidities. Furthermore, it provided transparency on data sources and flexibility, allowing the user to edit any of the inputs to test various assumptions and scenarios.
The model enabled users to actively compare the following outcomes after the introduction of the AOM against the current standard of care for obesity:
> Number of patients eligible for treatment
> Cost per year in the reference and in the new scenario
> Budget impact broken down by treatment option and cost type
> Key drivers of budget impact, through deterministic sensitivity analysis.
Value to the client
Our client was able to test various scenarios in multiple countries, allowing them to pursue their global market access strategy. The model was developed with a wide scope to ensure maximum utility for a range of stakeholders, including technical users and decision makers.